是葡萄糖类-1 (GLP-1) 感受体激动剂 中枢神经系统 (CNS) 透:叙事审查
Juliana West1, Maggie Li1, Sabrina Wong1,2
1Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.
Neurology and therapy
|April 2, 2025
概括
类似葡萄糖类-1受体激动剂 (GLP-1RA) 对神经疾病有前景,临床前研究表明,一些人穿过血脑屏障. 需要进一步的研究来证实它们对精神病理学的神经点的影响.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
背景情况:
- 类似葡萄糖的-1 (GLP-1) 是一种调节葡萄糖代谢和胰岛素分泌的隐形激素.
- GLP-1受体激活剂 (GLP-1RA) 模仿原生GLP-1,用于糖尿病和肥胖症.
- 新兴证据表明GLP-1RA可能为神经退行性疾病提供神经保护和疾病修饰.
研究的目的:
- 综合关于GLP-1RA的中枢神经系统 (CNS) 透性的文献.
- 通过脑成像研究来识别穿越血脑屏障 (BBB) 的GLP-1RA.
- 评估报告的GLP-1RA的中枢神经系统生物可用性.
主要方法:
- 在PubMed,Ovid和Web of Science的综合文献搜索到2024年7月.
- 包括关于特定GLP-1RA的临床前和临床研究 (18-80岁).
- 专注于报告中枢神经系统透或生物可用性的研究,通过脑成像进行代理.
主要成果:
- 综合包括了14项研究.
- 临床前数据表明,利拉格卢提德,塞马格卢提德和埃克萨纳提德可以穿过BBB.
- 人类研究表明,GLP-1 RA对大脑连接的影响可以作为中枢神经系统透的代理.
结论:
- 在临床前模型中,选择GLP-1RA证明了中枢神经系统的透性.
- 对于GLP-1RAs在多大程度上参与精神病理学的神经点,这一点尚未完全阐明.
关键词:
血脑屏障 血脑屏障 血脑屏障 血脑屏障杜拉古化物是什么?埃克森纳提德是什么意思这就是GLP-1.利拉格卢提德 (Liraglutide) 是一种类药物.石化酸是一种酸.塞马格卢提德 (semaglutide) 是一种类型的提尔泽帕提德是什么意思更多相关视频
相关概念视频
Glucose Absorption Into the Small Intestine
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and 'exit' via the...
Regulation of Food Intake
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...


